YouTube2Text

Prolactin Is THE Root Cause of Hair Loss?! Absci’s New Drug May Prove It — Transcript

by Perfect Hair Health · 9,752 words · 1,598 segments · language en · Watch on YouTube

Full transcript

  1. 0:00Decades of research tells us that the
  2. 0:01hormone DHT is the primary cause of
  3. 0:04pattern hair loss.
  4. 0:06But what if that's wrong? This isn't
  5. 0:08some hypothetical anymore. This is the
  6. 0:09position of a growing number of
  7. 0:11researchers, all stemming from the
  8. 0:14craziest monkey hair regrowth photos I
  9. 0:16have ever seen. Results achieved with a
  10. 0:19drug that didn't even touch DHT. Now a
  11. 0:22similar drug made by Absai, an
  12. 0:25AI-powered pharmaceutical company, is in
  13. 0:27phase two clinical trials to put this
  14. 0:30thesis to the test. I just interviewed
  15. 0:32the company's founder about their novel
  16. 0:34drug, their current clinical trials,
  17. 0:36their forthcoming results, which we'll
  18. 0:38get a peek at at the end of this year,
  19. 0:40and whether DHT is the root cause of
  20. 0:42pattern hair loss, or if perhaps another
  21. 0:45hormone is actually to blame. One that
  22. 0:47once we adequately target might unlock
  23. 0:50unprecedented levels of regrowth. Stick
  24. 0:52around, we're going to be covering it
  25. 0:53all, and for those new here, my name is
  26. 0:55Rob English. I research hair loss, I
  27. 0:57publish and review scientific papers
  28. 0:59about hair loss disorders, I serve on
  29. 1:00the editorial board of a dermatology
  30. 1:02journal, and I make videos like this for
  31. 1:04anybody who is fighting hair loss and
  32. 1:05looking for a path forward based on the
  33. 1:08evidence.
  34. 1:13This video is about the company Absai,
  35. 1:15their novel hair loss drug ABS 201, and
  36. 1:18the hormone that that drug targets. It's
  37. 1:21not DHT, it's prolactin. We'll get into
  38. 1:24what this hormone is, how this drug
  39. 1:25works, if the hype is real, and
  40. 1:28never-before-released data from Absai's
  41. 1:30founder, Shawn McLean, who we actually
  42. 1:32interviewed for this video. We talked
  43. 1:34for 2 hours, we asked him some very hard
  44. 1:36questions. For those short on time,
  45. 1:38please skip to this timestamp for the
  46. 1:40key takeaways on prolactin and hair
  47. 1:42loss, ABS 201, and whether I think this
  48. 1:45drug will succeed. And for everybody
  49. 1:47else, stick around. I'm about to tell
  50. 1:50you a story that is going to sound like
  51. 1:52a Hollywood hero's journey about hair.
  52. 1:55And it actually begins nearly a decade
  53. 1:57ago, not with Abside, but with another
  54. 1:59pharmaceutical company, Bayer, and an
  55. 2:01experiment that got some very unexpected
  56. 2:04results and changed the trajectory of
  57. 2:06their research project for many years.
  58. 2:12Back then, Andreas Busch, a researcher
  59. 2:15at Bayer, wanted to see if lowering
  60. 2:17prolactin levels might help improve a
  61. 2:19condition called endometriosis. So, his
  62. 2:21team set up an experiment in mice
  63. 2:23[music] and injected them with a drug
  64. 2:25that Bayer developed that would later be
  65. 2:26called HMI 115. We'll go deeper into
  66. 2:30this later, but at this stage, all you
  67. 2:32need to know is that this is a drug
  68. 2:34that, once injected, helps to lower
  69. 2:36levels of prolactin signaling in your
  70. 2:38cells. After injecting these mice,
  71. 2:41Andreas saw something unexpected. The
  72. 2:44mice who received HMI 115, the ones who
  73. 2:47had lowered prolactin activity, they
  74. 2:49actually saw faster hair regrowth
  75. 2:52compared to the mice who received a
  76. 2:53placebo injection. And so, he took these
  77. 2:55findings to Bayer and said, "I think we
  78. 2:57might have something here. I think we
  79. 2:59might have a candidate for a hair loss
  80. 3:01treatment." Now, you might be thinking
  81. 3:02at this stage,
  82. 3:04"Big deal."
  83. 3:05And I actually agree, because everything
  84. 3:07regrows hair on mice. Peppermint oil,
  85. 3:09copper peptides, sugar molecules, and
  86. 3:12more often than not, those same
  87. 3:14interventions inevitably fail to regrow
  88. 3:17hair appreciably in humans, because mice
  89. 3:20are not men. Mice don't naturally
  90. 3:22develop male pattern hair loss. And
  91. 3:24genetically spliced mice made to mimic
  92. 3:26that condition, they even still remain
  93. 3:29terrible proxies for treatment success,
  94. 3:31because candidly, we don't even know all
  95. 3:33the genes involved in male pattern hair
  96. 3:35loss to begin with. For more
  97. 3:36information, watch our video on evidence
  98. 3:38quality. Suffice it to say that mouse
  99. 3:40models rarely translate to human success
  100. 3:43with respect to androgenic alopecia
  101. 3:45treatments. But, there is another animal
  102. 3:47that isn't a human, and it does
  103. 3:49naturally go bald.
  104. 3:51Stump-tailed macaques. And while monkeys
  105. 3:53also aren't men, they tend to fare a bit
  106. 3:56better, at least as surrogates for
  107. 3:58research translatability doing
  108. 4:00treatments on hair loss. And Andreas
  109. 4:02felt that his mouse model results were
  110. 4:04strong enough that he convinced Bayer to
  111. 4:06commission a study on stumptailed
  112. 4:08[music]
  113. 4:08macaques. Inject them with prolactin
  114. 4:11receptor antibodies, monitor to see what
  115. 4:13happens with their scalps, and see if
  116. 4:16there truly might be something here. And
  117. 4:19this is where things get a little wild.
  118. 4:21Because after 6 months of treatment, the
  119. 4:24monkeys, they appeared totally fine. So,
  120. 4:27no issues related to adverse events that
  121. 4:29we know about, except they had regrown a
  122. 4:32ton of hair. And all by suppressing
  123. 4:35prolactin signaling in cells, not by
  124. 4:38touching DHT. And not only that, but
  125. 4:40when the monkeys actually were withdrawn
  126. 4:42from treatment, they were monitored for
  127. 4:44an additional 4 years, and to
  128. 4:46everybody's shock, during that time
  129. 4:48period, they actually continued to
  130. 4:50regrow hair. And not only that, but the
  131. 4:53older monkeys' hairs that had turned
  132. 4:55gray had actually repigmented. They went
  133. 4:57from gray back to colored. And why do I
  134. 5:00find this crazy? Because in all other
  135. 5:02monkey and human hair loss research that
  136. 5:04I have ever seen, I've first never seen
  137. 5:07this level of regrowth for hair
  138. 5:09recovery, and I've never seen this level
  139. 5:11of hair repigmentation. And in all other
  140. 5:14monkey and human hair loss research,
  141. 5:16when a treatment is officially
  142. 5:18withdrawn, you inevitably lose all the
  143. 5:21hair that you've regained. But in this
  144. 5:23study, the opposite happened. Despite
  145. 5:25the monkeys having stopped treatment,
  146. 5:28they continued to regrow hair, more and
  147. 5:30more. They continued to get better hair
  148. 5:32pigment, better and better. That is
  149. 5:34crazy. And it's something to get really
  150. 5:36excited about. And it was these findings
  151. 5:38that prompted Bayer to license their
  152. 5:40drug to Hope Medicine and expedite
  153. 5:43studies in humans. In 2023, a phase 1
  154. 5:46and phase 2 clinical study was launched,
  155. 5:49and for the next 12 months, everyone,
  156. 5:51including me, waited for the results
  157. 5:53thinking,
  158. 5:55"This might be it. This could be the
  159. 5:57breakthrough everybody has been waiting
  160. 5:59for. This could actually be the thing
  161. 6:01that takes somebody from nearly fully
  162. 6:02bald to fully haired." And then,
  163. 6:07nothing. Nothing. Nothing at all. In
  164. 6:092024, that research group announced that
  165. 6:12the phase 2 clinical studies had been
  166. 6:14completed,
  167. 6:15and then the company never even bothered
  168. 6:17submitting the results of the report.
  169. 6:20And then in 2025, a press release was
  170. 6:22issued about the phase 1 human study on
  171. 6:24HMI 115, on a whopping 16 people. The
  172. 6:28findings? It appeared safe,
  173. 6:30but it only regrew about 14 hairs per
  174. 6:32square centimeter. That's a far cry from
  175. 6:34the 100-plus hairs per square centimeter
  176. 6:37on average seen in that monkey study.
  177. 6:40And all of a sudden, enthusiasm
  178. 6:41surrounding HMI 115, and even
  179. 6:43prolactin's role in hair loss, all but
  180. 6:46collapsed. Well,
  181. 6:48all except for maybe one person, and
  182. 6:50that was Andreas Busch. He contended
  183. 6:53that the hypothesis on prolactin and
  184. 6:55hair loss still could be right, but that
  185. 6:57the monkey study did not translate to
  186. 6:59the humans not because of differences in
  187. 7:02hair loss pathology, but instead because
  188. 7:05he thought the humans were underdosed.
  189. 7:09That their prolactin wasn't adequately
  190. 7:10reduced in the way that it was for the
  191. 7:12monkeys, and that the pharmacokinetic
  192. 7:15data later released by Bayer
  193. 7:16Pharmaceuticals, according to him,
  194. 7:19actually proved it. And this is where
  195. 7:21Andreas Busch's journey moves from Bayer
  196. 7:23to another company, Abside, and from HMI
  197. 7:26115 to a partnership with Abside's
  198. 7:29founder, Shawn Maclean, and his research
  199. 7:32team to develop a better drug, one that
  200. 7:36fixed the problem in the original study
  201. 7:38on HMI 115, and one that would finally
  202. 7:41put to rest the thesis about prolactin
  203. 7:43whether it was actually at the root
  204. 7:44cause of hair loss.
  205. 7:47And this is where our conversation with
  206. 7:49Shawn McLean begins. I'll present this
  207. 7:51interview in two stages. First, I'm
  208. 7:55going to get out of Shawn's way. He has
  209. 7:57a compelling case to make about
  210. 7:58prolactin's role in hair loss, ABS-201,
  211. 8:01their ongoing clinical trials, and that
  212. 8:03steel man argument deserves to be
  213. 8:05presented uninterrupted. And only after
  214. 8:08that will I then show you my questions
  215. 8:10to Shawn and how that altered aspects of
  216. 8:13our discussion.
  217. 8:15>> Prolactin has
  218. 8:17maybe had a a bad rap and I think it was
  219. 8:20just due to
  220. 8:21the naming, you know, prolactin is you
  221. 8:24know, prolactation. Everyone thinks of
  222. 8:25it as a
  223. 8:27lactation hormone or or in women's
  224. 8:29health. But what you see is that
  225. 8:32prolactin is expressed all throughout
  226. 8:35the the body both in females but as well
  227. 8:39as males. You you actually see it in in
  228. 8:41the scalp. You see it in the the your
  229. 8:43joints.
  230. 8:44You you see it in in in your heart and
  231. 8:47in your bones. It and it and it plays a
  232. 8:50really interesting role.
  233. 8:52>> Shawn is describing our evolving
  234. 8:54understanding of the hormone prolactin.
  235. 8:57Originally only seen as a female
  236. 8:59hormone, researchers have now found that
  237. 9:01prolactin is actually all over the body
  238. 9:03in men and in women. And its role in
  239. 9:06human health is not just relegated to
  240. 9:08lactation.
  241. 9:09>> It looks like it sits on this
  242. 9:11stress inflammatory access, you know, in
  243. 9:15diseases like endometriosis or even
  244. 9:18androgenic alopecia it's driving,
  245. 9:20you know, inflammation. Essentially, we
  246. 9:23have new work that hasn't been published
  247. 9:24yet, but it looks like, you know, it
  248. 9:26does have a role in in in metabolism. I
  249. 9:28think we're just starting to realize
  250. 9:30how important prolactin's
  251. 9:33role is uh, in in both uh, male and
  252. 9:36females and you know, in in the role of,
  253. 9:39you know, androgenic alopecia,
  254. 9:41autoimmune diseases,
  255. 9:42uh, and, uh, and, and, uh, just a kind
  256. 9:45of immunology in general.
  257. 9:47>> So, Shawn sees prolactin as a hormone
  258. 9:49that's often elevated in conditions
  259. 9:51linked to inflammation, endometriosis,
  260. 9:54potentially some metabolic disorders,
  261. 9:56even androgenic alopecia. And at this
  262. 9:59stage, it's important to understand how
  263. 10:01prolactin is even arriving to these
  264. 10:03sites in the first place. Well, first,
  265. 10:05prolactin is made by our pituitary
  266. 10:07gland. That's the pea-sized organ that
  267. 10:09sits at the base of our brain. And that
  268. 10:11prolactin will enter our bloodstream and
  269. 10:13then travel through a highway network to
  270. 10:15other places in the body, where it can
  271. 10:18then attach to other organ sites and
  272. 10:20begin to influence the behavior of those
  273. 10:23cells. But according to Shawn, that's
  274. 10:24not the only way that our bodies make
  275. 10:26prolactin. There's also prolactin that
  276. 10:29our own organs can manufacture on site.
  277. 10:32And it's this production of prolactin
  278. 10:34that varies wildly in individuals. And
  279. 10:37it means that two people can have the
  280. 10:39same exact levels of blood prolactin,
  281. 10:41but then if you actually look at their
  282. 10:43tissue levels, they can be wildly
  283. 10:45different.
  284. 10:46>> So, you have the classical pituitary,
  285. 10:49um, expression of of prolactin, um, but
  286. 10:52then you also additionally have, and and
  287. 10:54a lot of people don't under, uh, or or
  288. 10:56know this, is that prolactin sits on a,
  289. 11:00uh, an additional promoter that controls
  290. 11:03the extra pituitary,
  291. 11:06um,
  292. 11:07uh, expression. And so, you could have
  293. 11:09normal systemic levels of prolactin that
  294. 11:13come from the pituitary, but it
  295. 11:15increased level of prolactin,
  296. 11:18uh, within the scalp. And and it's being
  297. 11:21driven off of that extra pituitary
  298. 11:23promoter. And what's really interesting
  299. 11:24is that the transcriptional, uh, uh,
  300. 11:29factors that that drive the extra
  301. 11:31pituitary, uh, um, expression are
  302. 11:33completely different than what you see
  303. 11:36in
  304. 11:37in the pituitary. So, they're completely
  305. 11:40independent. And I think that that's why
  306. 11:42for a long time
  307. 11:45this hasn't come up as a
  308. 11:48potential, you know, prolactin being a
  309. 11:49potential cause of of hair loss cuz
  310. 11:52we've been looking at you know, systemic
  311. 11:55blood levels
  312. 11:56versus looking at what is the the actual
  313. 12:00expression within the scalp. And you can
  314. 12:02have really high expression in the scalp
  315. 12:03but have completely normal prolactin
  316. 12:05levels. One of the things though that we
  317. 12:07don't really know is that
  318. 12:09how does systemic prolactin
  319. 12:13in addition contribute to what's being
  320. 12:15locally
  321. 12:17produced as as well. That's one of the
  322. 12:20you know, factors that we we still don't
  323. 12:22quite understand.
  324. 12:23>> Okay, so we see elevated levels of
  325. 12:25prolactin in organs affected by
  326. 12:26inflammation and autoimmunity. But just
  327. 12:29because something is higher in a
  328. 12:30diseased organ, that does not mean that
  329. 12:32the thing that's elevated is causing
  330. 12:34that disease. For a perfect example of
  331. 12:36this, look at blood levels of C-reactive
  332. 12:38protein or CRP. CRP is often elevated in
  333. 12:42people with actively evolving
  334. 12:44atherosclerosis.
  335. 12:45And so researchers once wondered if CRP
  336. 12:47was actually causing that
  337. 12:49atherosclerosis. But later research was
  338. 12:51able to tease out that this wasn't the
  339. 12:53case. That CRP was elevated as a
  340. 12:56reaction to other inflammatory
  341. 12:58processes. In other words, it wasn't a
  342. 13:01cause of the inflammation, it was an
  343. 13:02effect. It was a surrogate of the
  344. 13:04inflammation happening. So, in that same
  345. 13:06vein, what exactly is the evidence that
  346. 13:08causally links prolactin to androgenetic
  347. 13:11alopecia? Because I have to be honest
  348. 13:13with you, at first glance the idea of
  349. 13:15prolactin causing androgenetic alopecia
  350. 13:18sounds crazy. Because the name of the
  351. 13:20condition describes its causes.
  352. 13:22Androgens, male hormones like DHT, and
  353. 13:26genetic, your genes. And it's not like
  354. 13:28somebody just gave this condition this
  355. 13:30name and called it a day. These causes
  356. 13:32were established over 100 years of
  357. 13:35research. Men who can't produce the
  358. 13:37hormone DHT, they never go bald. When
  359. 13:40you expose balding sensitive scalp skin
  360. 13:42to DHT, it damages the hair follicles.
  361. 13:45And when you lower DHT levels in balding
  362. 13:48men with drugs like finasteride or
  363. 13:50dutasteride, 80 to 90% of them will see
  364. 13:53a slowing, stopping, or partial reversal
  365. 13:55of their hair loss with results
  366. 13:57sustaining for decades. So, you have
  367. 14:00decades of observational, mechanistic,
  368. 14:03and interventional data that all
  369. 14:05converge on the hormone DHT causing this
  370. 14:08condition. So, where on Earth does
  371. 14:10prolactin fit into this? And
  372. 14:12interestingly, Shawn doesn't refute
  373. 14:14DHT's role in androgenetic alopecia. He
  374. 14:17thinks it's absolutely causal. He just
  375. 14:19argues that DHT doesn't just magically
  376. 14:22appear in balding scalps. It increases,
  377. 14:25in part, because of prolactin. And not
  378. 14:28only that, but by targeting prolactin,
  379. 14:31he thinks we might even be able to
  380. 14:32overcome some of the biggest hurdles
  381. 14:35that prevent people from getting huge
  382. 14:37hair recoveries, even after they lower
  383. 14:39their DHT.
  384. 14:42>> The name is actually very misleading.
  385. 14:44Androgenetic alopecia, it implies that
  386. 14:47it's androgen driven. Yes, androgens are
  387. 14:49a part of it, but from what we're
  388. 14:51seeing, prolactin actually sits
  389. 14:54potentially upstream of the androgen
  390. 14:57receptor. And we actually even have data
  391. 14:59that that does show that
  392. 15:01um prolactin drives uh increase in
  393. 15:04androgen uh uh transcript. And and so,
  394. 15:07it does look like it regulates uh the
  395. 15:10androgen receptor.
  396. 15:11>> There's a lot to unpack here, but
  397. 15:13basically Shawn is suggesting that when
  398. 15:15prolactin arrives to a balding scalp, it
  399. 15:18activates androgen receptors, which are
  400. 15:20what cells use to allow hormones like
  401. 15:23DHT to attach to those cells and then
  402. 15:25exert their effects. And if I were to
  403. 15:28brutally simplify the old guard versus
  404. 15:30new guard or new hypothetical argument
  405. 15:33for androgenic alopecia, the old
  406. 15:35argument looks like this.
  407. 15:37After you hit a certain age, your
  408. 15:39genetics will cause DHT levels to rise
  409. 15:42in the scalp and those DHT levels will
  410. 15:44then cause pattern hair loss.
  411. 15:46What Sean is saying, it adds a a step
  412. 15:48right here and a step right here. So, it
  413. 15:50doesn't nullify decades worth of data.
  414. 15:52It just adds steps to what's happening
  415. 15:54and makes the chain of events a little
  416. 15:56more specific. So, that is the
  417. 15:57supposition.
  418. 15:59But, what is the evidence to support
  419. 16:01that supposition?
  420. 16:03In our interview, Sean builds his case
  421. 16:06starting with observational data on
  422. 16:07genes, prolactin, and severities of
  423. 16:10balding.
  424. 16:11>> What we did here was we we took a look
  425. 16:13at the UK Biobank and
  426. 16:17evaluated um
  427. 16:20how changes in prolactin
  428. 16:24expression or prolactin receptor
  429. 16:26expression uh
  430. 16:28change the the the the outcome of of
  431. 16:32balding. And and what we saw was was
  432. 16:36really really
  433. 16:38remarkable was that in those that were
  434. 16:42not balding or had very little balding,
  435. 16:45they had much lower prolactin receptor
  436. 16:49levels. And those individuals
  437. 16:53that had you know moderate to severe
  438. 16:55balding, you saw an increase in the
  439. 16:59overall
  440. 17:02prolactin receptor expression.
  441. 17:04>> So, to reiterate, Sean's team took
  442. 17:06genetic data from over 165,000
  443. 17:09men in a database and then he focused an
  444. 17:11analysis on genes that control for
  445. 17:13prolactin receptor expression in cells.
  446. 17:16Now, some genes will relate to more
  447. 17:18prolactin receptor expression, others
  448. 17:20less. And then his team compared those
  449. 17:23genes to the men's self-reported
  450. 17:26severities of hair loss, zero being no
  451. 17:28hair loss, four being severe hair loss.
  452. 17:31And they found that men with little to
  453. 17:32no hair loss also happen to have genes
  454. 17:35linked to lower prolactin receptor
  455. 17:37expression. And men with lots of hair
  456. 17:39loss had genes linked to higher
  457. 17:41prolactin receptor expression, which
  458. 17:43they also plotted in this chart.
  459. 17:45>> The thing that's
  460. 17:46remarkable about this is these are like
  461. 17:48very, very small changes in prolactin
  462. 17:51receptor expression.
  463. 17:54And by very small changes, you're still
  464. 17:58able to actually see an effect in in
  465. 18:01male pattern baldness.
  466. 18:03You know, these aren't massive changes
  467. 18:04in in overall expression, just minor,
  468. 18:06minor changes.
  469. 18:07>> But we know that association doesn't
  470. 18:09equal causation. Ice cream sales are
  471. 18:11linked to shark attacks, but ice cream
  472. 18:13sales do not cause shark attacks. The
  473. 18:16confounder is the warm weather getting
  474. 18:18people to buy ice cream, but also to go
  475. 18:20to the beach and also into the ocean.
  476. 18:22So, observation by itself is not enough.
  477. 18:26And then we have to ask, what else is
  478. 18:28there that might causally link prolactin
  479. 18:31to androgenic alopecia? Well, even
  480. 18:32before Absai and Bear thought to target
  481. 18:35prolactin for androgenic alopecia
  482. 18:37research, Sean actually told me about a
  483. 18:39research paper from 2006 by Ralph Paus,
  484. 18:42and it showed in biopsies of human hair
  485. 18:45follicles that hair follicles could make
  486. 18:47prolactin on site and that prolactin
  487. 18:50could also trigger those hairs to shed.
  488. 18:53So, that's a little data, but more
  489. 18:55interesting is some of the mechanistic
  490. 18:57work that Sean and his team later did to
  491. 19:00start to tease out cause and effect
  492. 19:01between prolactin and balding, some of
  493. 19:04which has not yet been made public until
  494. 19:06this interview.
  495. 19:07>> What we did here was we actually took
  496. 19:10human uh scalp biopsies uh of both male
  497. 19:13and female and what I'm showing you here
  498. 19:15is is male. And we then um cultured it
  499. 19:19in
  500. 19:20uh with ABS-201 uh which is uh our
  501. 19:24anti-prolactin receptor um blocking
  502. 19:26antibody. And uh additionally uh
  503. 19:30um cultured it with prolactin and then
  504. 19:32had a rescue arm where we added both
  505. 19:34prolactin as as well as uh ABS-201. And
  506. 19:39uh what you see here is uh how much hair
  507. 19:44uh was grown uh in a 3-day um period and
  508. 19:48this is, you know, that the same um type
  509. 19:50of measurement uh that is actually going
  510. 19:52to be done
  511. 19:53uh in
  512. 19:55uh the the clinical study uh looking at
  513. 19:57um the photography and seeing how much
  514. 19:59uh hair was actually grown and you can
  515. 20:01actually see here
  516. 20:02um within a 3-day time period ABS-201
  517. 20:07was able to uh increase hair growth. Uh
  518. 20:10and you you you saw um more hair
  519. 20:13follicles go into the uh anagen state
  520. 20:16and um prolactin um when you added it uh
  521. 20:20essentially shunted the overall growth
  522. 20:23and by adding both prolactin and uh the
  523. 20:25the receptor
  524. 20:27uh
  525. 20:27or
  526. 20:28uh or a and and the antibody, you're
  527. 20:30able to rescue uh the the follicle.
  528. 20:33>> So here Shawn's team took scalp biopsies
  529. 20:35from three balding men and then they
  530. 20:37exposed their skin to either nothing at
  531. 20:39all or their prolactin receptor antibody
  532. 20:42drug ABS-201
  533. 20:44or more prolactin or more prolactin plus
  534. 20:47ABS-201. Three days later, the samples
  535. 20:50exposed to ABS-201, they grew longer
  536. 20:53hair and they still had more of their
  537. 20:55hairs in the growth phase of their hair
  538. 20:56cycle than the samples that were left
  539. 20:58untouched or given more prolactin. The
  540. 21:00implication from this ex vivo research
  541. 21:02is that blocking prolactin might improve
  542. 21:05hair parameters in scalp skin samples of
  543. 21:07androgenic alopecia. Now, this is great
  544. 21:09and all, but growing longer hair or
  545. 21:11having hair is shed less frequently does
  546. 21:13not explain what happened in these
  547. 21:15stump-tailed macaques. These monkeys saw
  548. 21:18near full hair regeneration and near
  549. 21:20full hair repigmentation.
  550. 21:23This is a level of recovery that simply
  551. 21:25does not happen in humans with
  552. 21:27androgenic alopecia. It also is very
  553. 21:29rare to see in other monkey studies as
  554. 21:31well. In fact, in humans in specific,
  555. 21:33studies show that if you take your DHT
  556. 21:35as low as you can or you stimulate hair
  557. 21:38growth with drugs like minoxidil,
  558. 21:40on average, the best that you can expect
  559. 21:43is that you'll be able to rewind the
  560. 21:44clock on how your hair looks by around 6
  561. 21:47months to 36 months. That's an average.
  562. 21:49Some people do a little bit better, some
  563. 21:51people do a little worse, but after that
  564. 21:54point, it's like people hit a wall. You
  565. 21:56just don't get more hair back. And the
  566. 22:00question is why? And at least so far,
  567. 22:02researchers have identified three
  568. 22:04possible reasons.
  569. 22:05First, when you have advanced stages of
  570. 22:08hair loss, hair follicles will develop
  571. 22:10scarring or perifollicular fibrosis, and
  572. 22:12this might act like scaffolding that
  573. 22:14inevitably blocks hairs from shedding
  574. 22:16out and then re-sizing as thicker. So,
  575. 22:18in this case, you can reduce the DHT all
  576. 22:20you want. You can stimulate the hair to
  577. 22:21grow all you want, but if you don't get
  578. 22:23rid of that scaffolding, you're not
  579. 22:25going to be able to allow for the hairs
  580. 22:26to re-size as larger in subsequent hair
  581. 22:28cycles. Second, after hairs become
  582. 22:31miniaturized beyond a certain point,
  583. 22:33research suggests that they become
  584. 22:35detached from their goose bump muscle.
  585. 22:37That's the arrector pili muscle. And
  586. 22:39research so far seems to show that while
  587. 22:41we can save hairs that haven't yet
  588. 22:42detached from that muscle, we've not yet
  589. 22:45reliably seen evidence that any
  590. 22:48treatment available today can re-attach
  591. 22:50hairs that have detached from the
  592. 22:52arrector pili. So, hairs that are
  593. 22:54miniaturized beyond a certain point just
  594. 22:55don't seem to be able to be saved. And
  595. 22:58again, reduce all the DHT you want,
  596. 23:00growth stimulate all you want. If you
  597. 23:03can't get that attachment back, you're
  598. 23:04not going to recover those hairs. And
  599. 23:06the third possibility is that at some
  600. 23:08point in the balding process, hair
  601. 23:11follicle stem cells, which tend to be
  602. 23:13preserved even in advanced stages of
  603. 23:15hair loss, they start to lose their
  604. 23:17ability to convert from stem cells to
  605. 23:19other cell types like progenitor cells.
  606. 23:22And this failure step is why current
  607. 23:24treatments might not yet be able to
  608. 23:26fully revive those miniaturized hairs.
  609. 23:28And so, for a prolactin receptor
  610. 23:30antibody to do something like this in
  611. 23:33humans,
  612. 23:34that's not coming from hair elongation.
  613. 23:36It's not coming from a longer growth
  614. 23:38stage of your hair cycle. That's quite
  615. 23:40literally hair regeneration. It's taking
  616. 23:42a fully vellus hair and returning it to
  617. 23:44a fully terminal hair in many cases.
  618. 23:46It's solving, somehow, one of these
  619. 23:49rate-limiting regrowth factors that we
  620. 23:50know about in androgenic alopecia. And
  621. 23:52so, I asked Shawn about this and if his
  622. 23:54team had thought about this. And it
  623. 23:56turns out they had, and not only had
  624. 23:58they thought about it, but they had run
  625. 24:00an experiment, and they think they might
  626. 24:02actually have identified which of these
  627. 24:04rate-limiting recovery factors their
  628. 24:06treatment could address. It's the stem
  629. 24:08cell failure.
  630. 24:08>> One of the big things that that you see
  631. 24:11with
  632. 24:13balding individuals is that they lose
  633. 24:16their progenitor
  634. 24:18cells over time.
  635. 24:20And as you slowly lose those over time,
  636. 24:22you get more and more miniaturization
  637. 24:25that that occurs. Some of the data that
  638. 24:27that we generated
  639. 24:29where we were able to see that
  640. 24:32EBS
  641. 24:33201
  642. 24:35is able to
  643. 24:37actually increase the the proliferation
  644. 24:40of the K15 stem cell population,
  645. 24:45and it prevents the apoptosis,
  646. 24:48which is is really great to to see. You
  647. 24:51see prolactin on on on the right-hand
  648. 24:52side
  649. 24:54does drive apoptosis of the K15
  650. 24:59stem cell. And what's also really quite
  651. 25:02interesting
  652. 25:05is
  653. 25:07the progenitor
  654. 25:09cell line. What we see is the CD34 cells
  655. 25:15are are decreased
  656. 25:18when you add prolactin
  657. 25:20to these ex vivo
  658. 25:23models. Again, these are human
  659. 25:26scalp biopsies. And so we do believe
  660. 25:29that blocking prolactin receptor
  661. 25:33is is able to at least um
  662. 25:36keep the K15 stem cell population where
  663. 25:38it is and and be able to stop
  664. 25:41the CD34
  665. 25:44stem cell population from further
  666. 25:47depleting. So we we do think that there
  667. 25:49is this this ability to actually have a
  668. 25:51regenerative effect here. Currently,
  669. 25:55there is no therapy that is able to
  670. 25:59reverse that that that stem cell niche
  671. 26:02and, you know, potentially be able to
  672. 26:04reverse the miniaturization.
  673. 26:07And this is where we think ABS 201
  674. 26:10could have a big role.
  675. 26:13>> Here Shawn is saying that this
  676. 26:14mechanistic data suggests that if we
  677. 26:16block prolactin with ABS 201, we might
  678. 26:19also be able to stop hair follicle stem
  679. 26:21cell degradation, improve their
  680. 26:23differentiation into other cell types,
  681. 26:25and that we might be able to overcome
  682. 26:27this rate-limiting regrowth factor that
  683. 26:29other hair loss medications that exist
  684. 26:31today have failed to address. And that's
  685. 26:33how we might be able to explain these
  686. 26:35monkey results. But he also went a step
  687. 26:37further and he shared data not yet
  688. 26:39released in any public setting that he
  689. 26:41feels further corroborates this
  690. 26:43hypothesis.
  691. 26:44>> One of the
  692. 26:46phenotypes that has been shown is that
  693. 26:49collagen 17A
  694. 26:51uh
  695. 26:52over time with the the stem cell Um uh
  696. 26:55population and
  697. 26:57collagen 17A is really important uh in
  698. 27:00the sense that that is what anchors the
  699. 27:03stem cell population
  700. 27:05uh to the to the actual hair follicle
  701. 27:07itself. And what you see is that this
  702. 27:09gets degraded uh over time. And so the
  703. 27:13fact that you're actually modulating the
  704. 27:16stem cells in addition to increasing
  705. 27:20collagen 17A when blocking the the
  706. 27:23prolactin receptor uh is is really quite
  707. 27:27encouraging and and showing that indeed
  708. 27:30prolactin may sit upstream, you know, uh
  709. 27:33you know,
  710. 27:34you know, pretty far upstream where, you
  711. 27:37know, prolactin is is driving the the
  712. 27:39degradation of the stem cell niche. It
  713. 27:41Yeah, it uh you know, drives uh it
  714. 27:44doesn't replenish the collagen 17A and
  715. 27:47then it's it's driving the the
  716. 27:48inflammation that that you see as as
  717. 27:50well. And so
  718. 27:52uh we we are encouraged to uh see Again,
  719. 27:56this is a a 6-day
  720. 27:59uh culture. So, you you have to kind of
  721. 28:01take it for what it is, but it is a
  722. 28:03human biopsy and the the fact that we
  723. 28:06are seeing results in 6 days is is
  724. 28:10really incredible. The fact that you're
  725. 28:11actually regrowing that the hair,
  726. 28:13showing what prolactin uh you know,
  727. 28:15showing uh how prolactin
  728. 28:18uh is driving some of the same
  729. 28:19phenotypes that that we see
  730. 28:21uh in in prior research is is really
  731. 28:24quite exciting. And so you're you're
  732. 28:26hitting on
  733. 28:27kind of a
  734. 28:28a whole different mechanism that both
  735. 28:31minoxidil as well as uh the, you know,
  736. 28:34androgen receptor
  737. 28:36uh um
  738. 28:37um you know, mechanisms are are unable
  739. 28:39to uh to to to ultimately address. So,
  740. 28:43there it is. That's the hypothesis
  741. 28:45around prolactin and androgenic
  742. 28:47alopecia. In balding hair follicle
  743. 28:49sites, prolactin begins to increase.
  744. 28:52This causes a whole cascade of events.
  745. 28:54In one cascade, prolactin might increase
  746. 28:57androgen receptor expression, which then
  747. 28:59increases DHT, which then damages the
  748. 29:01hair follicles, causing them to shed
  749. 29:03prematurely, and then come back
  750. 29:05miniaturized in the next hair cycle. And
  751. 29:08simultaneously, in another cascade,
  752. 29:10prolactin may degrade collagen 17A,
  753. 29:13which anchors the hair follicle stem
  754. 29:15cell bulge to the hair follicle itself.
  755. 29:18And with enough degradation, this then
  756. 29:20prevents the conversion from hair
  757. 29:21follicle stem cells into progenitor
  758. 29:23cells, which then limits our ability to
  759. 29:25regenerate hair that's already fully
  760. 29:27miniaturized. Especially with
  761. 29:28DHT-reducing treatments like finasteride
  762. 29:30or dutasteride, or even some treatments
  763. 29:33for females that are more powerful
  764. 29:34androgen receptor antagonists like
  765. 29:36spironolactone, flutamide, and
  766. 29:38bicalutamide. Because these things, they
  767. 29:40only target part of the equation that
  768. 29:42Shawn proposes. But by blocking
  769. 29:44prolactin from reaching the hair
  770. 29:46follicle at all with a prolactin
  771. 29:48receptor antibody like ABS-201,
  772. 29:51Shawn argues that both of these
  773. 29:53disregulation cascades might get
  774. 29:56addressed. And that because we're
  775. 29:58addressing both simultaneously, rather
  776. 30:00than just one, and we're targeting
  777. 30:02something further upstream than just
  778. 30:04DHT, these crazy monkey regrowth results
  779. 30:07all of a sudden might become a reality
  780. 30:09for people. And with this model, the
  781. 30:11monkeys' continued hair regrowth even
  782. 30:13after quitting treatment becomes at
  783. 30:15least partly explainable. Because once
  784. 30:18those stem cell bulge connections are
  785. 30:20reestablished, hairs might just keep
  786. 30:22getting thicker and thicker in
  787. 30:24subsequent hair cycles regardless of
  788. 30:26whether you're continuing that
  789. 30:27treatment. Because it also takes time to
  790. 30:29build them, and it takes time to degrade
  791. 30:32them as well. So, it's an enticing
  792. 30:33hypothesis.
  793. 30:35But then, if the hypothesis is even
  794. 30:37true, why did HMI 115 fail to regrow
  795. 30:40hair appreciably in humans? I mean, it
  796. 30:43barely got any regrowth.
  797. 30:45Well, this is where Andreas Busch, the
  798. 30:46man who ran the original HMI 115 studies
  799. 30:49in monkeys, teams up with Sean and
  800. 30:52proposes a data-driven conviction. The
  801. 30:55hypothesis on HMI 115 and prolactin was
  802. 30:58not wrong.
  803. 31:00The humans in the study were simply
  804. 31:02underdosed. And it's this very premise
  805. 31:05that led Andreas Busch, Sean, and Absi
  806. 31:08to develop a new drug and rerun this
  807. 31:10hair loss experiment in humans in what's
  808. 31:13currently a phase two clinical trial
  809. 31:15going on right now. Now, here's what
  810. 31:17Sean had to say about the differences
  811. 31:19between HMI 115 and ABS-201.
  812. 31:24There are a lot of technical terms here.
  813. 31:26I will stop and explain them as we go,
  814. 31:28but this is the core thesis behind what
  815. 31:30Sean's company hopes will become a
  816. 31:32billion-dollar drug.
  817. 31:34>> What you saw in the stump-tailed
  818. 31:36macaques was 90% receptor occupancy. And
  819. 31:42what you saw from the HMI 115 data from
  820. 31:45the P So, they they publicly released
  821. 31:47the PK data, and then we modeled the RO
  822. 31:51based off of of that. And it's it's
  823. 31:53really quite quite
  824. 31:55shocking. And yeah, I think you'll
  825. 31:57you'll you'll see why we're
  826. 32:00quite confident in the profile that we
  827. 32:03have.
  828. 32:03>> Okay, so what is Sean talking about? 90%
  829. 32:06receptor occupancy, PK data. What does
  830. 32:08all this mean? Well, first, Sean is
  831. 32:11referring to what he describes as
  832. 32:12publicly released pharmacokinetic data
  833. 32:15on HMI 115. PK stands for
  834. 32:18pharmacokinetics. That's basically just
  835. 32:20the study of how a drug behaves in your
  836. 32:22body. Where it goes, how long it stays
  837. 32:25there, that kind of stuff. And what Sean
  838. 32:27is saying is that in this study on
  839. 32:29monkeys, HMI 115 was able to block 90%
  840. 32:34of those monkeys' prolactin receptors.
  841. 32:36In other words, HMI 115 achieved 90%
  842. 32:39receptor occupancy. And this is
  843. 32:41important because the more prolactin
  844. 32:43receptors occupied by HMI 115, the less
  845. 32:47that prolactin can then attach to that
  846. 32:49cell, and the less that prolactin can
  847. 32:51then affect it. So, the more that you
  848. 32:54block, the less prolactin will have as
  849. 32:56an influencer on that cell's behavior.
  850. 32:59And at least in this monkey study, when
  851. 33:01you hit 90% receptor occupancy for
  852. 33:04prolactin, it seems to be doing some
  853. 33:07really impressive things. But, this is
  854. 33:08the critical point that Shawn is about
  855. 33:10to make.
  856. 33:11>> What's really interesting about the
  857. 33:13prolactin receptor
  858. 33:16is that you have to block it pretty
  859. 33:19substantially
  860. 33:21in order to completely block it. What do
  861. 33:25I mean by this? Even if you're at, let's
  862. 33:28say,
  863. 33:2960, uh, 70, even, you know, 80%
  864. 33:33um, receptor occupancy, you could still
  865. 33:35have full activity of the the actual um,
  866. 33:39pathway until
  867. 33:41uh, you block it um, you know,
  868. 33:43substantially.
  869. 33:44>> Now, what Shawn is talking about here is
  870. 33:46a concept known as receptor reserves, or
  871. 33:48spare receptors. Basically, this is a
  872. 33:51biological phenomenon where for certain
  873. 33:53hormones, your cells will express a ton
  874. 33:56of receptors to capture them. Such that
  875. 33:58a majority of those receptors that are
  876. 34:00active probably aren't even needed.
  877. 34:02They're considered spares. One of the
  878. 34:05most dramatic examples of this is with
  879. 34:07the hormone insulin. In muscle cells,
  880. 34:10you can have 100 insulin receptors
  881. 34:12available, and yet insulin only needs to
  882. 34:15attach to one of them to exert its
  883. 34:17maximal metabolic effects on that muscle
  884. 34:20cell. In other words, it doesn't matter
  885. 34:22if insulin attaches to just one
  886. 34:24receptor, or 99 of the receptors. The
  887. 34:28cell's behavior does not change after
  888. 34:30one. So, if you wanted to create an
  889. 34:32insulin receptor blocker that was
  890. 34:34effective, you'd literally need to find
  891. 34:36one of that blocked as close to 100% of
  892. 34:39insulin receptors as possible. Because
  893. 34:41if the blocker only blocks 99% of them,
  894. 34:44that medication has zero effect. And it
  895. 34:46turns out this same receptor reserve
  896. 34:49relationship may also exist with
  897. 34:51prolactin. For instance, in one study on
  898. 34:53lymphoma, prolactin hit its maximal
  899. 34:57effect on cell growth at just 35%
  900. 35:00receptor occupancy. So, you could be at
  901. 35:0235% or 100% and the same growth
  902. 35:06trajectory occurred. And what this means
  903. 35:07is that if you made a prolactin receptor
  904. 35:09blocker that blocked a whopping 65% of
  905. 35:12prolactin receptors, well, in this
  906. 35:14lymphoma study, your prolactin receptor
  907. 35:17blocker would still be 100% useless. In
  908. 35:20fact, in that study, even if you blocked
  909. 35:22prolactin receptors by 80%, you'd still
  910. 35:25see prolactin exerting more than 90% of
  911. 35:27its maximal growth effect on those
  912. 35:30cells. So, think of it like failing a
  913. 35:32test. It doesn't matter if you got a 59
  914. 35:34out of 100 or a one out of 100, you're
  915. 35:37still getting an F. And so, now the
  916. 35:39question becomes with HMI 115, these
  917. 35:42monkeys were suspected to hit 90%
  918. 35:45receptor occupancy, RO.
  919. 35:48But, did the same actually happen in the
  920. 35:51human clinical trials? According to Sean
  921. 35:54and Andreas Busch, the answer is no.
  922. 35:57>> What you see from HMI 115 data here.
  923. 36:00Again, this was
  924. 36:02they publicly disclosed what the PK
  925. 36:05profile was in their phase one. We then
  926. 36:07modeled out what the RO would be based
  927. 36:10off of the the publicly available data.
  928. 36:13And you you see that
  929. 36:16it takes quite a bit of time
  930. 36:18for the HMI 115 molecule
  931. 36:21to actually
  932. 36:23ramp up to Um, yeah, but 70% uh receptor
  933. 36:28occupancy is is the the Cmax or 72 73
  934. 36:32and it then oscillates.
  935. 36:35Now,
  936. 36:36what's the significance of the
  937. 36:38oscillation? So,
  938. 36:39when you block prolactin receptor, you
  939. 36:42actually get an increase in prolactin
  940. 36:44levels.
  941. 36:46And if you then dip below a certain
  942. 36:49receptor occupancy threshold, you could
  943. 36:51actually be activating the the prolactin
  944. 36:54receptor with the increased levels of
  945. 36:57prolactin that are in the system. So,
  946. 37:00you're inadvertently going in between
  947. 37:03anagen and catagen, anagen catagen,
  948. 37:05anagen catagen.
  949. 37:07And we know that it takes time to
  950. 37:10rebuild the stem cell niche. And you
  951. 37:12need a sustained
  952. 37:15uh level of receptor occupancy for a
  953. 37:18long period of time
  954. 37:20uh to be able to rebuild that stem cell
  955. 37:22niche. And we believe this is the reason
  956. 37:26why uh HMI 115 did not
  957. 37:30uh achieve the the full efficacy because
  958. 37:33they they weren't able to give the hair
  959. 37:36follicle kind of a long enough time to
  960. 37:39uh actually rebuild that stem cell niche
  961. 37:41um because it was kind of constantly
  962. 37:43oscillating in and out of anagen and and
  963. 37:46catagen um phase versus, you know, what
  964. 37:48you see with with our molecule is that
  965. 37:51you get uh sustained levels of greater
  966. 37:55than 90% receptor occupancy for for 6
  967. 37:58months uh straight
  968. 38:00uh and and and we're above the 90%
  969. 38:03receptor occupancy, which again is what
  970. 38:05you saw in in the stump tail macaques.
  971. 38:07And uh again,
  972. 38:10we believe in the mechanism based on
  973. 38:12everything we've we've told you.
  974. 38:14It just came down to a PK inducing issue
  975. 38:18with HMI 115. So, now you have the core
  976. 38:21thesis behind ABS201. Andreas, Shawn,
  977. 38:24the broader Absite team, they developed
  978. 38:26this drug to solve for this receptor
  979. 38:28occupancy problem. And their phase one
  980. 38:31and pharmacokinetic studies, according
  981. 38:32to Shawn, prove that ABS201 achieves a
  982. 38:36prolactin receptor occupancy level of
  983. 38:39greater than 90%. That's a lot. And
  984. 38:41being above that 90% receptor occupancy
  985. 38:44threshold, according to Shawn through
  986. 38:46inferences in this monkey data, is the
  987. 38:48level that you need to adequately
  988. 38:50suppress prolactin levels in hair
  989. 38:51follicles. Which, with sustained
  990. 38:54suppression, will hopefully give the
  991. 38:56stem cell bulge enough time to rebuild,
  992. 38:58which is what we need to achieve truly
  993. 39:00regenerative effects in humans. And it's
  994. 39:03this very premise that guided Shawn's
  995. 39:06team through preclinical work, then
  996. 39:08phase one human studies for safety, and
  997. 39:10now a phase two human study on men and
  998. 39:14women with androgenic alopecia. And
  999. 39:16this, Shawn believes, is the test that
  1000. 39:19we need to truly ascertain if this
  1001. 39:21hypothesis surrounding prolactin and
  1002. 39:23hair holds validity. And if this
  1003. 39:26treatment target might be the
  1004. 39:28breakthrough the entire hair loss
  1005. 39:29community has been waiting for. This
  1006. 39:31phase two study, it is already underway,
  1007. 39:33and in December of this year, Shawn and
  1008. 39:36his team plan to do a preliminary
  1009. 39:3813-week read and an announcement of the
  1010. 39:41data.
  1011. 39:42>> The 13-week data read out that's going
  1012. 39:44to come in December. We have not given
  1013. 39:48firm metrics on what we would like to
  1014. 39:50achieve there. We have talked about it
  1015. 39:53being directional. We want to see that
  1016. 39:55the mechanism is is is working and that
  1017. 39:57there is kind of a path to
  1018. 40:0030 plus hairs per square centimeter at
  1019. 40:02at at 26 week. And so, I think that we
  1020. 40:05have set ourselves up
  1021. 40:07in a way that again, this is a more an
  1022. 40:09exploratory look at how the mechanism is
  1023. 40:14is performing to to to
  1024. 40:18Additionally,
  1025. 40:19we do feel good about the readout at 26
  1026. 40:23weeks, but
  1027. 40:25let's say we achieve a 30 plus
  1028. 40:28at 26 weeks. My guess is that
  1029. 40:329 12 months, you continue to see an
  1030. 40:35increase from from there. But, you know,
  1031. 40:38we are confident
  1032. 40:40that
  1033. 40:42you'll see, I think, strong or good
  1034. 40:46results at at at 26 weeks, but that
  1035. 40:48doesn't take away from the fact that you
  1036. 40:50could continue to see
  1037. 40:52hair regrowth past
  1038. 40:546 months. And And the great part about
  1039. 40:56that is we are actually going to be
  1040. 40:58tracking these patients for a year post
  1041. 41:01treatment. So, we are going to
  1042. 41:02understand like how
  1043. 41:05the you know, how how the changes are
  1044. 41:08are progressing over over that year post
  1045. 41:11treatment. So, I think that that'll also
  1046. 41:13be a really exciting
  1047. 41:14insight that we're going to see as well.
  1048. 41:16>> And here's the part that I really
  1049. 41:17appreciated about my conversation with
  1050. 41:19Shawn. So, I voiced to him about how
  1051. 41:22frustrated I've been this year and last
  1052. 41:24year with all of the press releases from
  1053. 41:25other companies that are pursuing future
  1054. 41:27hair loss treatments.
  1055. 41:28The through line here is that there is a
  1056. 41:31massive amount of data withholding,
  1057. 41:33manipulation of statistics, disingenuous
  1058. 41:35comparisons across hair count groups,
  1059. 41:37subgroup of subgroup analyses, the
  1060. 41:39absence of reporting of critical metrics
  1061. 41:41like absolute terminal hair count
  1062. 41:42changes. And so, I just asked him
  1063. 41:44directly that regardless of these
  1064. 41:4513-week results, if it would be possible
  1065. 41:48if he could commit to just not pulling
  1066. 41:50any of these weird statistical stunts or
  1067. 41:52obscurities in the way that data is
  1068. 41:54reported. And here is what he said.
  1069. 41:56>> I can promise you that we will have a
  1070. 41:59non-controversial
  1071. 42:01data cut. We are not going to do a
  1072. 42:02subpopulation of subpopulation like it
  1073. 42:05it's going to be
  1074. 42:06clear-cut uh
  1075. 42:08data that will be
  1076. 42:11uh to to interpret. And that to me is
  1077. 42:13amazing news. So, kudos to Shawn for
  1078. 42:16this, and in December or January, you
  1079. 42:18can bet that I'll be making a follow-up
  1080. 42:19video about that press release and the
  1081. 42:22data. I hope that it is fantastic.
  1082. 42:25So, this about wraps the steel man case
  1083. 42:27for prolactin, its role or potential
  1084. 42:30role in androgenic alopecia, HMI 115,
  1085. 42:33why it supposedly failed, the evolution
  1086. 42:35to ABS-201, and how lowering prolactin
  1087. 42:38might unlock near full levels of hair
  1088. 42:40regrowth. And I really want to present
  1089. 42:42Shawn and the broader data here in the
  1090. 42:44strongest way possible. I wanted to slow
  1091. 42:46down the storytelling to reiterate
  1092. 42:48information that was key, to add support
  1093. 42:50where I could, because he reached out to
  1094. 42:53us. He gave me a ton of time. We had two
  1095. 42:55calls. The first one was an hour, the
  1096. 42:57second one was two hours. He's committed
  1097. 42:59to giving public an uncontroversial
  1098. 43:01reads of ABS-201's 13-week data.
  1099. 43:04And that part of the discussion here
  1100. 43:06deserves to stand alone without my
  1101. 43:08interruptions, without my nitpicking,
  1102. 43:10because it truly is a service that Shawn
  1103. 43:12took the time to do this. But I
  1104. 43:13obviously asked Shawn a ton of questions
  1105. 43:15during our conversations, because I
  1106. 43:17wanted to improve my clarity on the
  1107. 43:19strengths, but also the limitations of
  1108. 43:21the evidence presented. And in this
  1109. 43:22respect, I always think that we should
  1110. 43:24remain hopeful about future treatments
  1111. 43:26and the work going into them. But in
  1112. 43:28general, it usually helps to have a
  1113. 43:31precaution to temper expectations about
  1114. 43:34what a clinical trial is going to do,
  1115. 43:36because
  1116. 43:37as it stands, I think the data around
  1117. 43:39prolactin and hair loss is compelling in
  1118. 43:41some respects and limited and
  1119. 43:44potentially conflicting in others. And
  1120. 43:46I'll get into that level by level right
  1121. 43:48now.
  1122. 43:50First, let's start off with HMI 115's
  1123. 43:53monkey data.
  1124. 43:54The results are absolutely incredible. I
  1125. 43:56mean it when I say that I've never seen
  1126. 43:58monkey results to this degree, and the
  1127. 44:00continued hair regrowth post-treatment
  1128. 44:02withdrawal, I have never seen that in
  1129. 44:04any androgenic alopecia study, monkey or
  1130. 44:06human, before. But, is this magnitude of
  1131. 44:08regrowth truly unrivaled in monkey
  1132. 44:10studies? Not necessarily. While it's not
  1133. 44:13the same recovery, take a look at this
  1134. 44:16study on stump-tailed macaques and
  1135. 44:17minoxidil. In humans, topical minoxidil
  1136. 44:20tends to produce relatively modest hair
  1137. 44:22gains. The cosmetic results tend to peak
  1138. 44:24around 6 to 8 months, and then you
  1139. 44:26plateau and even slowly decline
  1140. 44:28thereafter.
  1141. 44:29But, in this monkey study, the monkeys
  1142. 44:31using minoxidil, they just kept
  1143. 44:34regrowing hair. They regrew hair at
  1144. 44:35month three, at month six, and at month
  1145. 44:37nine. In fact, they kept regrowing more
  1146. 44:39and more hair all the way up until they
  1147. 44:41withdrew from treatment. So, these
  1148. 44:43monkey models can directionally
  1149. 44:45translate to humans with androgenic
  1150. 44:47alopecia. But, they're not perfect
  1151. 44:50surrogates by any means. In fact, in my
  1152. 44:51opinion,
  1153. 44:53I think that reconverting vellus hairs
  1154. 44:55into terminal hairs in monkeys is just a
  1155. 44:57ton easier than it is in humans because
  1156. 44:59the treatments that seem to do it in
  1157. 45:00monkeys, like minoxidil, when you apply
  1158. 45:03those to humans, you don't get the same
  1159. 45:05results. You get the same directional
  1160. 45:08results, you don't get the same
  1161. 45:10magnitude of results. And it's not just
  1162. 45:13minoxidil. We've also seen the magnitude
  1163. 45:15of results really decrease with other
  1164. 45:17treatments. When latanoprost or
  1165. 45:19bimatoprost moved from monkey models to
  1166. 45:22humans, they went from pretty impressive
  1167. 45:25results to very tiny, ambiguous, and
  1168. 45:28cosmetically insignificant results. So
  1169. 45:31again, we have to temper our
  1170. 45:33expectations. What we see in these
  1171. 45:34monkeys directionally might fit with
  1172. 45:36humans, but the magnitude of impact, it
  1173. 45:38might be very tiny. We don't know yet.
  1174. 45:42Next, let's talk about this genetic data
  1175. 45:44that Shawn presented. Now, Shawn showed
  1176. 45:45us some charts suggesting that genes
  1177. 45:47linked to higher prolactin receptor
  1178. 45:48expression were also linked to higher
  1179. 45:51severities of balding. And Shawn noted
  1180. 45:53in the interview that all it took were
  1181. 45:55just tiny differences in prolactin
  1182. 45:57receptor expression to show this
  1183. 45:59relationship in the severities of
  1184. 46:01balding. However, this observational
  1185. 46:03relationship to me appears somewhat at
  1186. 46:06odds with the idea that prolactin is a
  1187. 46:08hormone with high spare receptors or
  1188. 46:11receptor reserves. So, for instance, if
  1189. 46:15this gene for prolactin receptor
  1190. 46:16expression is linked to little to no
  1191. 46:18hair loss, but this gene is linked to a
  1192. 46:21ton of hair loss. And yet, the
  1193. 46:23difference in prolactin receptor
  1194. 46:24expression across the genes is maybe 10,
  1195. 46:2720, 30, 50, 70% even if it's 80%.
  1196. 46:31Then what difference does that make if
  1197. 46:33all prolactin needs to do to trigger
  1198. 46:35hair loss is occupy 10% of those
  1199. 46:39available prolactin receptors? With such
  1200. 46:41a low threshold for prolactin to
  1201. 46:42potentially have these adverse hair
  1202. 46:44effects, wouldn't that imply that micro
  1203. 46:47differences in prolactin receptor
  1204. 46:48expression shouldn't matter at all? That
  1205. 46:50instead, we would want to see 10 or
  1206. 46:5220-fold differences in expression
  1207. 46:54activity before we start to see these
  1208. 46:56problems?
  1209. 46:58And yet, we can't really answer these
  1210. 46:59questions right now because the data is
  1211. 47:01so preliminary, but it's also really
  1212. 47:03limited.
  1213. 47:05Next, let's talk about some of the ex
  1214. 47:07vivo data that Shawn presented. These
  1215. 47:09studies on balding hair follicles are
  1216. 47:11great mechanistic tools for research.
  1217. 47:14But the one relationship that they don't
  1218. 47:16establish is if all these same
  1219. 47:18directional relationships with hair also
  1220. 47:22exist in non-balding scalp hair. Because
  1221. 47:25if prolactin also does all the same
  1222. 47:27exact things at the same exact
  1223. 47:29magnitude. It stops hair elongation. It
  1224. 47:32turns hairs from growing into resting.
  1225. 47:35If it does that the same in balding hair
  1226. 47:37samples as it does in non-balding hair
  1227. 47:40samples, then this would actually weaken
  1228. 47:42the case for prolactin causing
  1229. 47:44androgenic alopecia. So, I asked Shawn
  1230. 47:46about this in the interview and if they
  1231. 47:47had done experiments with non-balding
  1232. 47:49human scalp hair as well. And here was
  1233. 47:51his response.
  1234. 47:52>> Really quickly, so we can see that
  1235. 47:54there's some degree of significance with
  1236. 47:57those effect sizes on the slides you
  1237. 47:59just showed. Those are from three male
  1238. 48:01scalp biopsies with androgenic alopecia.
  1239. 48:04Do you have control data on a scalp
  1240. 48:07unaffected by androgenic alopecia as a
  1241. 48:09comparator of any type?
  1242. 48:11>> Uh
  1243. 48:12we do not. We took it from an androgen
  1244. 48:14sensitive uh area, uh
  1245. 48:17which is the frontal temporal uh region.
  1246. 48:20Um but we did not have a
  1247. 48:25uh healthy or a
  1248. 48:27um
  1249. 48:28non uh
  1250. 48:30um
  1251. 48:31you know, balding sensitive uh area. Um
  1252. 48:35so so we currently do not have that at
  1253. 48:36the moment.
  1254. 48:37>> Okay. Yeah, I'd be really curious to see
  1255. 48:39if you see the same exact drops in an
  1256. 48:43unaffected AGA scalp skin sample as
  1257. 48:45well. Because then that would help to
  1258. 48:47tease out whether or not those drops are
  1259. 48:48truly relevant to the mechanisms being
  1260. 48:51explored.
  1261. 48:52>> Yeah, absolutely. And uh one of the
  1262. 48:55things that I think will will will see
  1263. 48:58uh actually before we even get data like
  1264. 48:59that is actually how this performs in in
  1265. 49:01in humans later this year.
  1266. 49:03>> Now, for what it's worth, Shawn's reply
  1267. 49:05here is fair. You could spend your whole
  1268. 49:08life running ex vivo studies trying to
  1269. 49:10guess what happens in a human.
  1270. 49:11Eventually, you just need to prove
  1271. 49:13safety as best as you possibly can and
  1272. 49:15move on to human testing. But without
  1273. 49:17those non-balding control samples, I
  1274. 49:19personally don't find this mechanistic
  1275. 49:21data nearly as compelling. And the same
  1276. 49:24criticisms apply to research presented
  1277. 49:26about collagen 17A. It's a fascinating
  1278. 49:29hypothesis, new research indicates this
  1279. 49:31could be a critical piece to the balding
  1280. 49:33process, and a rate-limiting recovery
  1281. 49:35factor with respect to androgenic
  1282. 49:37alopecia treatment success. But without
  1283. 49:39knowing how non-balding hairs also react
  1284. 49:42and also express collagen 17A, we can't
  1285. 49:45actually distinguish if any increased
  1286. 49:48expression or decreased expression of
  1287. 49:50anything is meaningful and if it's truly
  1288. 49:53unique just to balding affected skin.
  1289. 49:56And this matters even more when we
  1290. 49:58actually revisit that original 2006
  1291. 50:00paper from Ralph Paus. And we actually
  1292. 50:02see that in that study the effects of
  1293. 50:05prolactin on human hair follicles, they
  1294. 50:08were coming from non-balding hair
  1295. 50:10follicles. And yet the researchers found
  1296. 50:12the same relationships.
  1297. 50:14This study used occipital regions of the
  1298. 50:17scalp during facelifts and hair
  1299. 50:19transplant surgeries. And in both cases
  1300. 50:21those should be hairs that are
  1301. 50:22relatively protected from the balding
  1302. 50:24process that aren't as prone to DHT's
  1303. 50:27mediating effects on androgenic
  1304. 50:28alopecia. And yet in that 2006 study,
  1305. 50:31the same relationship seemed to exist
  1306. 50:33with a non-balding human hair follicle
  1307. 50:35as we're now seeing in the balding human
  1308. 50:37hair follicle research 20 years later.
  1309. 50:41Next, there's the discussion about
  1310. 50:43safety, about lowering prolactin levels
  1311. 50:46in cells and whether or not that's
  1312. 50:47something that's safe long-term.
  1313. 50:50In women, hyperprolactinemia is
  1314. 50:52associated with an inability to lactate
  1315. 50:54and it's also associated with
  1316. 50:55infertility. Now on their own website,
  1317. 50:57Absi sites papers to suggest that
  1318. 51:01reducing prolactin is potentially very
  1319. 51:03safe for many adverse events.
  1320. 51:06But they mainly focus on safety metrics
  1321. 51:08that are not fertility and not
  1322. 51:09lactation. And because of this I wanted
  1323. 51:11to understand not only which adverse
  1324. 51:14events of interest Shawn's team will be
  1325. 51:16tracking in their clinical study, I also
  1326. 51:18wanted to know how they were tracking
  1327. 51:20the adverse events themselves. And
  1328. 51:23there's a very specific reason why I
  1329. 51:24wanted to ask this. I will show you the
  1330. 51:26clip here.
  1331. 51:27>> You mentioned Veridermis just a second
  1332. 51:29ago. I've been tracking their data as
  1333. 51:31well. I think that anybody innovating
  1334. 51:33and attempting to run
  1335. 51:35well-designed studies in the hair loss
  1336. 51:37space for interventions is incredible.
  1337. 51:40So I really appreciate what they're
  1338. 51:41trying to do. When I looked at their
  1339. 51:45clinical data and specifically their
  1340. 51:46adverse events. I saw some things that
  1341. 51:49didn't make total sense to me. So, we
  1342. 51:51know that their formulation is
  1343. 51:54uh
  1344. 51:55a larger dose of minoxidil that is
  1345. 51:56supposed to slowly leak into your system
  1346. 51:58over time.
  1347. 51:59>> [snorts]
  1348. 52:00>> And when we look at all of the clinical
  1349. 52:02studies on oral minoxidil ranging from
  1350. 52:040.25 mg and higher, 60%
  1351. 52:09of participants, both male and female,
  1352. 52:11across literally all of the studies
  1353. 52:13report hypertrichosis.
  1354. 52:15And when I looked at Verodermal safety
  1355. 52:16data, I saw the hypertrichosis numbers
  1356. 52:19at something like 3 to 6% which was
  1357. 52:22comparable to the placebo group. So,
  1358. 52:24this means that either they have
  1359. 52:26inadvertently developed a hyper-targeted
  1360. 52:28oral minoxidil that then attaches only
  1361. 52:31to the scalp and does not affect hair
  1362. 52:33anywhere else on the body, which is not
  1363. 52:35listed in any of their patents,
  1364. 52:37or there is something with their data
  1365. 52:40collection with respect to safety that
  1366. 52:42is not adequately capturing the real
  1367. 52:44risk of hypertrichosis that we would
  1368. 52:46expect for this medication, which then
  1369. 52:48leads me to the question about how your
  1370. 52:50team in your phase two clinical studies
  1371. 52:52is capturing clinical adverse events
  1372. 52:55reporting.
  1373. 52:56Are these done through interviews with
  1374. 52:58the investigators? Are these done
  1375. 53:01through survey systems? Are they done
  1376. 53:03through open-ended questionnaires? Each
  1377. 53:05of these has their pros and their cons
  1378. 53:07and there's plenty of debate as to which
  1379. 53:09is the best in clinical research and
  1380. 53:11reporting, but I'm curious just to get
  1381. 53:13your perspective on how you are tracking
  1382. 53:15these things earlier we were talking
  1383. 53:17about libido and the potential for no
  1384. 53:21effect, maybe even benefit from this
  1385. 53:24type of therapy,
  1386. 53:25but then libido is separate from semen
  1387. 53:28parameters and you can have a strong
  1388. 53:29libido and be completely infertile. And
  1389. 53:32so, I'm just kind of curious at this
  1390. 53:33point for how you guys in your phase two
  1391. 53:35clinical research have pre-specified how
  1392. 53:37you'll collect adverse events and the
  1393. 53:39specific adverse events that you are
  1394. 53:41exploring.
  1395. 53:43>> Yeah, it's a great question. So, first
  1396. 53:45off, we have a fantastic chief medical
  1397. 53:49officer. Uh he was the the SVP and head
  1398. 53:54of clinical development at Vertex. Prior
  1399. 53:57to that, he was at
  1400. 53:59Amgen and you know, has you know,
  1401. 54:0120-plus years of
  1402. 54:03very hardcore clinical development
  1403. 54:06experience
  1404. 54:07at you know, well outside of even you
  1405. 54:09know, he's he's run some of the most
  1406. 54:11complex and and hard clinical trials. He
  1407. 54:14actually ran a you know, the Jornavik's
  1408. 54:16the the NAV 1.8 clinical study, which is
  1409. 54:20a pain study. And pain studies are
  1410. 54:22notoriously very very challenging and
  1411. 54:25and was successful in in that study. And
  1412. 54:28so, he has brought a lot of rigor into
  1413. 54:33Absai on the clinical development side.
  1414. 54:36And we are wanting to make sure that we
  1415. 54:39have a robust
  1416. 54:42study. And you know, we believe with how
  1417. 54:45we have set up this study, if
  1418. 54:48successful, we see this as a
  1419. 54:50potentially a dose range finding study,
  1420. 54:53where we can go on to a phase three
  1421. 54:56clinical study. And and in terms of like
  1422. 54:59the overall clinical operations, the
  1423. 55:01protocols that that we have in in place,
  1424. 55:04I can say that they're of the the
  1425. 55:05highest standard. And
  1426. 55:09you know, these
  1427. 55:10you know, the the questionnaires and and
  1428. 55:11how they're asked, they're they're all
  1429. 55:13done
  1430. 55:14in a way to really help
  1431. 55:17do it in an unbiased
  1432. 55:19way. And and we have a really incredible
  1433. 55:22clinical development team. On all the
  1434. 55:24specific you know, details,
  1435. 55:26we'd have to bring him on to to kind of
  1436. 55:28go through all of those. But I I I do
  1437. 55:31know though that
  1438. 55:33it is a is a very rigorous study. And
  1439. 55:36you know, you can even look at how we
  1440. 55:38designed the the phase two clinical
  1441. 55:40study. It's a, you know, it's a three to
  1442. 55:42one
  1443. 55:43um,
  1444. 55:45placebo
  1445. 55:47controlled
  1446. 55:48double-blinded study,
  1447. 55:51and yeah, really excited about the the
  1448. 55:53overall
  1449. 55:55kind of results both on the efficacy as
  1450. 55:58well as being able to ensure that the
  1451. 56:01you know, adverse
  1452. 56:02events are are
  1453. 56:04recorded and and
  1454. 56:06done in an appropriate manner.
  1455. 56:07>> By the way, I'll link our video on
  1456. 56:09Veridermics below if you caught that
  1457. 56:10comment. But in any case, Shawn
  1458. 56:12preferred in this case to defer
  1459. 56:14answering this to his head of clinical
  1460. 56:16development.
  1461. 56:17Also, it is totally fine to do that.
  1462. 56:19He's the CEO of Absi. He's not in the
  1463. 56:22weeds leading every aspect of the
  1464. 56:24clinical research projects. But adverse
  1465. 56:26event tracking and how it's reported is
  1466. 56:28one piece of a clinical trial protocol
  1467. 56:31that basically almost never gets
  1468. 56:33published publicly in a repository, but
  1469. 56:35that is super important to understand
  1470. 56:38because the way that you collect results
  1471. 56:40can drastically change the outcomes. And
  1472. 56:42those differences in results don't
  1473. 56:44actually reflect product safety
  1474. 56:45differences. They just reflect
  1475. 56:46differences in the way that data was
  1476. 56:48collected, and that's the issue. So
  1477. 56:50perhaps in the future we can get a
  1478. 56:51little bit better clarity on this, and
  1479. 56:53it'll be one of the things that I'd love
  1480. 56:55to focus on if and when it's time to see
  1481. 56:57Absi's clinical data or if we're able to
  1482. 56:59connect with their head of clinical
  1483. 57:01research.
  1484. 57:03Next, for veterans of the hair loss
  1485. 57:05community, you will know that we have
  1486. 57:07reached this milestone in research for
  1487. 57:10hair loss treatments many times before.
  1488. 57:12Where observational, mechanistic, and
  1489. 57:14even early interventional data all point
  1490. 57:17toward a new novel breakthrough just
  1491. 57:20around the corner for androgenic
  1492. 57:21alopecia, only for the human clinical
  1493. 57:23trial to fail miserably.
  1494. 57:25One recent example, prostaglandin D2
  1495. 57:28antagonism. Specifically, the drug
  1496. 57:31setipiprant.
  1497. 57:32Observational data found that
  1498. 57:34prostaglandin D2 was elevated in balding
  1499. 57:36scalps. Mechanistic data suggested PGD2
  1500. 57:39stopped hair lengthening. Monkey data on
  1501. 57:41prostaglandin analogs like latanoprost,
  1502. 57:44bimatoprost, even to a certain extent
  1503. 57:46minoxidil, all showed impressive hair
  1504. 57:49gains. And yet, when a prostaglandin D2
  1505. 57:51inhibitor setipiprant was finally tested
  1506. 57:54in men with androgenic alopecia,
  1507. 57:56there was literally no effect at all.
  1508. 57:58So, remain hopeful, but don't forget
  1509. 58:02about the graveyard of prior prospective
  1510. 58:04treatments that made it all the way to
  1511. 58:07this point, only to still fail a
  1512. 58:09clinical trial. Statistically, it is the
  1513. 58:12phase two human study that tends to make
  1514. 58:15or break most real contenders in the
  1515. 58:18hair loss treatment space.
  1516. 58:20And lastly, this one I really love. Even
  1517. 58:23if ABS-201 fails, it still actually does
  1518. 58:27not disprove the hypothesis that
  1519. 58:29prolactin might be a root cause of
  1520. 58:31androgenic alopecia. It might turn out
  1521. 58:33that it's still just not powerful enough
  1522. 58:35of a prolactin receptor antibody. Keep
  1523. 58:38in mind that that lymphoma study I
  1524. 58:40talked about earlier, even when
  1525. 58:41prolactin occupied just 7% of the
  1526. 58:44available receptors, cell growth was
  1527. 58:47still at 50% its maximal speed. In this
  1528. 58:50respect, we might actually find that a
  1529. 58:51failed clinical trial on ABS-201 simply
  1530. 58:54means that we have to build something
  1531. 58:55that suppresses prolactin even harder.
  1532. 58:57It's wild to think about that fact that
  1533. 59:00even with ABS-201, a drug that was
  1534. 59:02designed to overcome this one liability,
  1535. 59:04we still might not be able to confirm or
  1536. 59:07rule out the legitimacy of the
  1537. 59:08hypothesis. And that is just the way
  1538. 59:11that hair loss research goes.
  1539. 59:14Okay, that is everything. I know this
  1540. 59:16video was a long one. I hope that you
  1541. 59:18enjoyed it. I hope that you learned
  1542. 59:19something. We put a ton of time into
  1543. 59:21creating it. And I really wanted to
  1544. 59:23thank Shawn for taking the time to reach
  1545. 59:25out and do this interview with us. I
  1546. 59:27loved our discussion. I really
  1547. 59:29appreciated his time and most
  1548. 59:31importantly, I want his product to
  1549. 59:33succeed. I think that if it does, it's
  1550. 59:35going to be an incredible compliment or
  1551. 59:37even a replacement to every other
  1552. 59:39treatment out there. We can only hope
  1553. 59:42and time will only tell. We'll know more
  1554. 59:44at that 13-week data read. However, even
  1555. 59:47if the results are very tiny at 13
  1556. 59:49weeks, recall that the monkeys took 4
  1557. 59:52years for significant hair regeneration.
  1558. 59:55You can't look at the data at 13 weeks
  1559. 59:57for efficacy. I think that would be a
  1560. 59:59huge mistake. What we should be looking
  1561. 1:00:02at here is whether or not the prolactin
  1562. 1:00:04receptor antibodies are safe. What are
  1563. 1:00:07people reporting in terms of fertility
  1564. 1:00:10markers, libido markers, anything else
  1565. 1:00:13that's an adverse event of interest?
  1566. 1:00:15That is what's most important at this
  1567. 1:00:17read. Even if hair counting data looks
  1568. 1:00:20flat or slightly negative, I am not
  1569. 1:00:22discouraged by that. It is 13 weeks. So,
  1570. 1:00:25give it more time. Speaking of time, if
  1571. 1:00:27you are fighting hair loss, you have to
  1572. 1:00:29make do with the treatments that are
  1573. 1:00:31available today. And if you're
  1574. 1:00:33interested in pursuing treatments that
  1575. 1:00:35are hyper-personalized and
  1576. 1:00:36evidence-based, I helped co-found the
  1577. 1:00:38brand ULO, that's ulo.co,
  1578. 1:00:42to facilitate access to those
  1579. 1:00:43treatments. We're US-based telehealth
  1580. 1:00:46brand focused exclusively on hair loss
  1581. 1:00:49and we deliver what I would consider an
  1582. 1:00:50unrivaled level of personalization to
  1583. 1:00:53make sure you're getting the best
  1584. 1:00:54possible outcomes that respect your
  1585. 1:00:56needs, but also your preferences. We
  1586. 1:00:58have low-dose formulations of topical
  1587. 1:00:59finasteride and topical dutasteride,
  1588. 1:01:02their full-strength counterparts. We
  1589. 1:01:04have topical minoxidils paired with
  1590. 1:01:06retinoic acid or tretinoin. We offer
  1591. 1:01:08high-strength oral dutasteride,
  1592. 1:01:10standard-dose oral dutasteride,
  1593. 1:01:12standard-dose finasteride, and a lot of
  1594. 1:01:15other options to help facilitate your
  1595. 1:01:17journey. I hope you check out the brand
  1596. 1:01:18and in the meantime, we'll keep making
  1597. 1:01:20content like this. I hope you enjoy it.
  1598. 1:01:22I look forward to next time.

About this transcript

This page contains the full transcript of Prolactin Is THE Root Cause of Hair Loss?! Absci’s New Drug May Prove It by Perfect Hair Health, generated from the public captions YouTube serves with the video. The transcript has 9,752 words across 1,598 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.